Which treatment is currently recommended for Kawasaki Disease?

High-dose immunoglobulin G and aspirin are the cornerstone treatments recommended for Kawasaki Disease. This inflammatory vasculitis primarily affects children and can lead to significant complications, including coronary artery aneurysms. High-dose immunoglobulin (IVIG) is administered to reduce inflammation and the risk of developing these cardiovascular complications. Administering aspirin serves a dual purpose: it provides anti-inflammatory effects and helps reduce the risk of thrombosis due to platelet activation associated with the disease process.

The use of antibiotics and steroids is not appropriate for Kawasaki Disease since it is not an infectious or an autoimmune process requiring steroid therapy; rather, it involves a complex inflammatory response. Statins and blood thinners are also not indicated because they target cholesterol levels and clotting issues, which are not the primary concerns in Kawasaki Disease. ACE inhibitors and diuretics are primarily used to manage hypertension and heart failure, conditions which do not align with the mechanisms or needs of Kawasaki Disease.

Therefore, the combination of high-dose immunoglobulin G and aspirin is the standard treatment that effectively addresses both the inflammation and the risk of serious cardiac complications associated with this condition.